Structure Therapeutics Inc. Form 8-K Summary
Business context and reporting period
Structure Therapeutics Inc., a Cayman Islands biopharmaceutical company listed on Nasdaq under the symbol GPCR, filed this Current Report on Form 8-K regarding a change in its independent registered public accounting firm. The earliest reported event date was May 31, 2023; the report was signed and filed on June 5, 2023.
Key financial metrics and reporting matters
This filing does not provide current revenue, profit, cash flow, margins, debt, liquidity, or other operating metrics.
PwC’s audit reports on the Company’s financial statements for the years ended December 31, 2022 and 2021 contained neither adverse opinions nor disclaimers and were not qualified or modified for uncertainty, audit scope, or accounting principles.
Material changes versus the prior comparable period
- On May 30, 2023, the Audit Committee approved the dismissal of PricewaterhouseCoopers LLP (PwC); PwC was notified on May 31, 2023.
- On May 30, 2023, the Audit Committee approved the engagement of Ernst & Young LLP (EY) for the fiscal year ending December 31, 2023. EY was appointed on May 31, 2023, effective after PwC’s dismissal was communicated.
- The Company reported no disagreements with PwC regarding accounting principles or practices, financial statement disclosure, or audit scope or procedures during the fiscal years ended December 31, 2022 and 2021 or the subsequent interim period through May 31, 2023.
- The Company also reported no reportable events other than previously disclosed material weaknesses in internal control over financial reporting.
Guidance, outlook, risks, contingencies, and unusual items
The filing provides no financial guidance or business outlook. It reiterates the existence of material weaknesses involving the control environment, segregation of duties within the financial reporting function, and information technology general controls relevant to financial statement preparation. These weaknesses existed during 2021 and 2022 and through May 31, 2023.
The Company stated that neither it nor anyone acting on its behalf consulted with EY during the relevant periods regarding specified accounting transactions, potential audit opinions, disagreements, or reportable events.
Important facts for investors to verify
- Review Exhibit 16.1, PwC’s letter to the SEC dated June 5, 2023, for PwC’s response to the Company’s disclosures.
- Review the Company’s Form 10-K for the year ended December 31, 2022 and Form 10-Q for the quarter ended March 31, 2023 for remediation plans and the status of the disclosed internal control weaknesses.
- Confirm EY’s role as the independent registered public accounting firm for the fiscal year ending December 31, 2023.
- Assess whether the auditor transition or unresolved internal control weaknesses affects the timing, reliability, or scope of future financial reporting.